{
    "clinical_study": {
        "@rank": "166360", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "post-operative radiotherapy will be done in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy Dose of Radiotherapy: 45 Gray Gy/30 fractions/3 weeks"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "adjuvant chemotherapy (gemcitabine and cisplatin) in addition to post operative radiotherapy in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "Adjuvant chemotherapy alone in locally advanced bladder cancer patients (P3b, P4a, G3 and / or LN positive patients) after radical cystectomy"
            }
        ], 
        "brief_summary": {
            "textblock": "Radical Cystectomy is still the standard treatment in muscle-invasive Bladder cancer. Local\n      recurrence is still the major cause of failure together with distant metastasis.\n      postoperative radiotherapy   succeeded   to decrease the local recurrence and hence improved\n      the overall survival. Adjuvant chemotherapy has also improved the survival in different\n      studies. This study is performed to test the efficacy and toxicity  of adding the two\n      modalities together compared to each modality alone."
        }, 
        "brief_title": "Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Locally Advanced Bladder Cancer", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients not more than 70 years old.\n\n          -  Radical cystectomy performed within 42 days with no microscopic or macroscopic\n             residual after surgery (negative surgical safety margins)\n\n          -  Having one or more of the risk factors ( P3b,P4a,G3 and /or positive LN)\n\n          -  ECOG Performance Scale (0-2).\n\n          -  Adequate liver functions.\n\n          -  Adequate renal function serum (creatinine < 1.5 mg).\n\n          -  No evidence of distant metastasis or other malignancy.\n\n        Exclusion Criteria:\n\n          -  patients who received radiotherapy or chemotherapy prior to radical cystectomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "198", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01734798", 
            "org_study_id": "Bladder-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "intervention_name": "Radiation", 
                "intervention_type": "Radiation"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "intervention_name": "gemcitabine and cisplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "intervention_name": "Radiotherapy and Drug", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "locally advanced bladder cancer", 
            "Postoperative radiotherapy", 
            "Adjuvant chemotherapy", 
            "Radical Cystectomy"
        ], 
        "lastchanged_date": "November 22, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "National cancer Institute-Cairo University"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Regular follow up is performed every 2 months in the first 2 years postcystectomy and every 6 months thereafter.  Periodical CT pelvis is performed every 6 months in the first 2 years and yearly thereafter. The other appropriate radiological studies are performed in response to patients' symptoms and signs. Treatment side effects (immediate and late) are reported in each follow up visit.", 
            "measure": "Comparison of the disease-free survival and overall survival of post-operative radiotherapy , adjuvant chemotherapy  and the combined modalities [radiotherapy and chemotherapy] after radical cystectomy", 
            "safety_issue": "Yes", 
            "time_frame": "Five-year overall and disease-free survival."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01734798"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cairo University", 
            "investigator_full_name": "Mohamed s. Zaghloul", 
            "investigator_title": "Professor of Radiation Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Periodical CT pelvis is performed every 6 months in the first 2 years and yearly thereafter. The other appropriate radiological studies are performed in response to patients' symptoms and signs. Treatment side effects (immediate and late) are reported in each follow up visit.", 
            "measure": "comparison of the Local recurrence rate in the three Arms", 
            "safety_issue": "Yes", 
            "time_frame": "Five year local pelvic control rate"
        }, 
        "source": "Cairo University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cairo University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}